{"filings":[{"id":2088518,"accession_number":"0001792044-26-000037","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-08-06T11:56:03+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q2 2026: Revenue $3.8B (+5%), GAAP net loss $119M, raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3.8B, up 5% reported and 3.5% operationally vs Q2 2025; GAAP net loss $119M.","Adjusted EBITDA $1.2B, up 8% operationally; gross leverage ratio reduced to 2.9x.","Raised 2026 financial guidance midpoints for all metrics; expects balanced H2.","Returned ~$550M to shareholders including ~$270M share repurchases through early August.","Pipeline milestones: U.S. FDA approval of Gwyn Lo; sale of global rights to Tyrvaya."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1388316,"accession_number":"0001140361-26-027216","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-07-01T20:20:55+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Viatris enters ¥40B amended term loan facility, refinances prior 2021 facility","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["¥40,000,000,000 senior unsecured term loan facility, matures July 1, 2029 (three years from closing).","Proceeds used to repay existing ¥40B term loan from July 2021; interest at TIBOR + 1.10% initially.","Financial covenant: leverage ratio no greater than 3.75 to 1.00 as of each fiscal quarter end.","Guarantors include Mylan Inc., Utah Acquisition Sub Inc., Mylan II B.V., and other subsidiaries guaranteeing >$500M debt.","Mizuho Bank acts as administrative agent; Mizuho, MUFG, SMBC as mandated lead arrangers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1138520,"accession_number":"0001140361-26-025744","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-06-18T20:10:51+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Viatris closes €650M 4.250% Senior Notes due 2033 to refinance 2026 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€650M aggregate principal, 4.250% coupon, matures June 17, 2033; interest payable annually.","Net proceeds to repay $1.675B 3.950% Senior Notes due 2026 and for general corporate purposes.","Notes are senior unsecured, guaranteed by Mylan Inc., Mylan II B.V., Utah Acquisition Sub Inc.","Make-whole redemption at T+25bps prior to April 17, 2033; thereafter at par; change-of-control put at 101%.","Covenants restrict sale-leaseback, liens, subsidiary guarantees, and mergers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1057516,"accession_number":"0001140361-26-025228","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-06-15T20:32:33+00:00","items":["8.01","9.01"],"status":"ready","headline":"Viatris issues €650M of 4.250% Senior Notes due 2033","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Principal amount: €650,000,000 at 4.250% interest, maturing 2033.","Underwriters led by BNP PARIBAS, Citigroup Global Markets, and Goldman Sachs.","Offering expected to close on June 17, 2026, subject to customary conditions.","Issued under Form S-3 shelf registration and prospectus supplement dated June 12, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":471637,"accession_number":"0001140361-26-021672","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-05-15T20:30:24+00:00","items":["5.07"],"status":"ready","headline":"Viatris shareholders elect all 13 directors, approve executive compensation, ratify Deloitte & Touche","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 13 director nominees elected; votes For ranged from 798.5M (JoEllen Lyons Dillon) to 871.8M (Elisha Finney).","Non-binding advisory vote on 2025 executive compensation approved: 846.4M For, 26.9M Against.","Ratification of Deloitte & Touche LLP as independent auditor for FY2026 approved: 969.3M For, 27.7M Against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95487,"accession_number":"0001792044-26-000025","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q1 revenues $3.5B (+8% YoY), adj. EBITDA $1.0B, reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3.5B, up 8% reported and 3% operational vs Q1 2025.","US GAAP net earnings $176M; Adjusted EBITDA $1.0B, +10% operationally.","Reaffirms 2026 financial guidance; expects >$2.5B cash available for deployment.","Launched Effexor for generalized anxiety disorder in Japan; pipeline milestones progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":3517000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95486,"accession_number":"0001140361-26-018887","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris CFO Theodora Mistras to depart; Paul Campbell appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Financial Officer Theodora Mistras voluntarily ceases role effective May 8, 2026, to pursue another professional opportunity.","Paul Campbell, Chief Accounting Officer and Corporate Controller, appointed interim CFO effective May 8, 2026.","Mistras will remain employed through May 22, 2026, for transition; not eligible for severance or equity vesting.","Mistras eligible for pro rata bonus for 2026 based on actual performance, subject to release and restrictive covenants.","Viatris to release Q1 2026 results on May 7, 2026, and host conference call at 8:30 a.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108605,"accession_number":"0001792044-26-000010","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","2.05","8.01","9.01"],"status":"ready","headline":"Viatris Q4 2025 revenue $3.7B, FY $14.3B; announces restructuring with $700-850M charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $3.7B, FY2025 total revenues $14.3B; met or exceeded all 2025 guidance metrics.","Returned over $1B to shareholders in 2025; expects balanced capital allocation for 2026.","Global workforce reduction of up to ~10%; total pre-tax restructuring charges $700-850M.","Enterprise-wide strategic review completed; expects $650M cost savings with up to $250M reinvestment over 3 years.","Anticipates regulatory decisions for six product candidates and multiple pipeline milestones in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":14299900000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108604,"accession_number":"0001140361-26-003477","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2026-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Viatris Chief Legal Officer Brian Roman departs Feb 9; Matthew Maletta appointed successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Roman to cease as Chief Legal Officer on Feb 9, 2026; remains employee until April 1 for transition.","Roman eligible for separation payments: base salary plus target bonus and pro rata 2026 bonus, subject to release.","Matthew Maletta joins as Chief Legal Officer on Feb 9; previously EVP, Chief Legal Officer and Secretary of Endo, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125056,"accession_number":"0001140361-25-044706","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viatris to sell Biocon Biologics stake for $815M in cash and equity from Biocon Limited","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Viatris receives $400M cash and $415M in newly issued Biocon Ltd shares for Biocon Biologics convertible preferred equity.","Biosimilars non-compete restrictions end immediately ex-U.S., by Nov 2026 in U.S., accelerating Viatris' market access.","Transaction expected to close in Q1 2026; subject to closing conditions and taxes; Citi acted as financial advisor.","CEO Scott A. Smith says deal provides significant optionality and advances Viatris' strategic evolution.","Biocon shares subject to six-month lock-up; consideration subject to related taxes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125055,"accession_number":"0001140361-25-044544","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Viatris shareholders elect 13 directors, approve say-on-pay, ratify Deloitte at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 13 director nominees elected; lowest support was JoEllen Lyons Dillon with 779M for vs 72M against.","Advisory vote on 2024 named executive officer compensation approved: 831M for, 38.6M against.","Ratification of Deloitte & Touche as independent auditor approved with 963.7M for, 25M against.","Broker non-votes of ~117M shares on director election and say-on-pay had no effect on outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125052,"accession_number":"0001140361-25-044541","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K/A","filed_at":"2025-12-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Viatris appoints David Simmons to Compensation and Science & Technology Committees","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Simmons added to Compensation Committee effective after 2025 annual meeting.","Also appointed to Science and Technology Committee effective post-2025 annual meeting.","Amendment to Aug 4 2025 8-K that reported Simmons' board appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125054,"accession_number":"0001792044-25-000042","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q3 results in line, raises FY guidance; acquires Aculys Pharma; NDA for estrogen patch","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Total revenues for Q3 2025 in line with expectations; raising and narrowing 2025 guidance for revenues, adjusted EBITDA, adjusted EPS.","Submitted NDA for low-dose estrogen weekly patch; advancing pipeline.","Acquired Aculys Pharma, gaining rights to Pitolisant (Japan) and Spydia (Japan & Asia-Pacific).","Year-to-date capital return >$920M, including $500M in share repurchases.","CEO cites strong execution and strategic review for sustainable growth in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":10596300000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125053,"accession_number":"0001140361-25-039269","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["5.03","5.08","8.01","9.01"],"status":"ready","headline":"Viatris amends bylaws on proxy access timing, sets 2026 annual meeting for May 15","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved Amended and Restated Bylaws, effective October 24, 2025, revising Section 2.16(b) on proxy access nomination notice.","2026 annual meeting of shareholders scheduled for May 15, 2026; details in upcoming proxy statement.","Shareholder director nominations for 2026 meeting must be received between Jan 15 and Feb 14, 2026.","Proxy access nominations (3% holder for 3+ years) due by Jan 15, 2026; early window opens Dec 16, 2025.","Rule 14a-8 proposals for 2026 proxy must be received by Nov 24, 2025; universal proxy notice deadline Mar 16, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141750,"accession_number":"0001792044-25-000031","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q2 revenues beat expectations; reaffirms 2025 guidance, returns $630M+ to shareholders","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Q2 total revenues exceeded company expectations; specific figures not disclosed.","Returned over $630M of capital to shareholders YTD, including $350M in share buybacks.","Late-stage pipeline momentum with positive Phase 3 data readouts from five studies.","Reaffirmed all 2025 guidance metrics; expects top half of range for total revenues and adjusted EPS.","FY 2025 operating cash flow guidance: $2.2B–$2.5B (midpoint ~$2.35B)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":6836400000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141749,"accession_number":"0001140361-25-028739","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris appoints ex-PPD CEO David Simmons to board; board expands to 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Simmons appointed independent director effective August 4, 2025; board size increased from 14 to 15.","Simmons was Chairman/CEO of PPD (led to $17.4B sale to Thermo Fisher), 15+ years at Pfizer, CEO of Caliber Holdings.","No related-party transactions or arrangements per Item 404(a) of Regulation S-K.","Committee assignments pending; compensation consistent with other non-employee directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159645,"accession_number":"0001792044-25-000016","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris reaffirms 2025 outlook after Q1 results; returns >$450M to shareholders YTD","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Total revenues in Q1 2025 in line with expectations; three positive Phase 3 data readouts achieved.","Year-to-date share repurchases over $300 million; total capital returned >$450 million.","2025 net cash from operations guided at $2.2-2.5 billion (midpoint ~$2.35B); outlook reaffirmed.","CEO cites pipeline progress and operational execution as drivers of confidence in full-year guidance.","Full Q1 financial details not provided in this excerpt; reliance on summary statements."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":3254300000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159644,"accession_number":"0001140361-25-017356","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris appoints Frank D'Amelio and Michael Severino to Board; Rajiv Malik and Harry Korman to retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Frank D'Amelio (former Pfizer CFO) and Michael Severino (Tessera CEO) appointed independent directors effective May 5, 2025.","Rajiv Malik and Harry Korman will retire at end of current terms in December after the 2025 Annual Meeting.","D'Amelio appointed to Finance Committee; Severino to Science and Technology Committee.","Both new directors bring pharmaceutical and executive experience; company cites ongoing board refreshment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178023,"accession_number":"0001792044-25-000004","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris reports FY2024 revenue $14.7B, GAAP net loss $634M, adj EPS $2.65; guides 2025 share buybacks $500-650M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenues $14.7B; GAAP net loss $634M ($0.53 diluted loss); adjusted EPS $2.65.","Free cash flow $2.0B (incl. ~$650M transaction costs) exceeded guidance; repaid $3.7B debt; leverage 2.9x.","New product revenues $582M; 2025 expects six Phase 3 readouts for selatogrel, cenerimod, sotagliflozin.","2025 guidance includes Indore facility warning letter/import alert impact; enterprise cost review initiated.","Plans $500M-$650M share repurchases in 2025; returned $825M to shareholders in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":14739300000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194707,"accession_number":"0001193125-24-272562","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Viatris shareholders reject say-on-pay proposal; approve 49M share increase for equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding say-on-pay proposal failed with 49.23% in favor (458.9M against, 5.4M abstain).","Shareholders approved amendment to 2020 Stock Incentive Plan increasing authorized shares by 49 million.","All 12 director nominees elected; JoEllen Lyons Dillon received lowest support (737.8M for, 167.7M against).","Deloitte & Touche ratified as auditor for FY2024 with 962.95M votes in favor.","Broker non-votes of ~115M shares reported on proposals 1, 2 and 4."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194706,"accession_number":"0001792044-24-000031","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q3 2024: Revenue $3.8B, GAAP EPS $0.08, Adjusted EPS $0.75, Repaid $1.9B Debt","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3.8B, operational revenue growth ~3% on divestiture-adjusted basis; new product revenues $133M.","GAAP net earnings $95M ($0.08 diluted EPS); adjusted EBITDA ~$1.3B (+4% divestiture-adjusted); adjusted EPS $0.75 (+6%).","Repaid ~$1.9B debt including make-whole call; expects to reach ~3.0x gross leverage target by year-end.","Entered exclusive licensing agreement with Lexicon for sotagliflozin outside U.S. and Europe.","Reaffirms 2024 full-year outlook: ~2% revenue growth on divestiture-adjusted operational basis."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":11211200000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211008,"accession_number":"0000950157-24-001314","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Viatris enters $3.5B revolving credit facility, replacing $4B revolver","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $3.5B facility includes $300M LC subfacility and $175M swingline sublimit.","Facility matures in five years; leverage covenant max 3.75:1 as of each fiscal quarter end.","Initial interest rate SOFR + 1.10% or base rate + 0.10%; facility fee 0.15%.","Proceeds used for general corporate purposes and to repay existing $4B facility.","Viatris can seek added commitments if pro forma leverage compliance is maintained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211007,"accession_number":"0000950157-24-001164","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viatris launches cash tender offers for up to ~$1.8B in notes due 2025-2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Any and all of $750M 1.650% Senior Notes due 2025 (Viatris) and €500M 2.125% Senior Notes due 2025 (Mylan) sought.","Up to $450M of $2.25B 3.950% Senior Notes due 2026 (Utah Acquisition) with $30/$1,000 early tender premium.","Any and All Tender Offers expire Sept 10, 2024; Maximum Tender Offer expires Oct 2, 2024; early tender deadline Sept 17.","If less than all Viatris 2025 notes tendered, company may satisfy and discharge indenture; Mylan may redeem remaining.","Barclays, Citigroup, and J.P. Morgan act as dealer managers for the offers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211006,"accession_number":"0001792044-24-000022","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q2: GAAP net loss $326M, adjusted EPS $0.69 up ~3%; raises new product revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3.8B, operational growth ~2% on divestiture-adjusted basis; GAAP revenue declined ~3%","GAAP net loss of $326M ($0.27 diluted loss per share); adjusted EPS $0.69, up ~3% on divestiture-adjusted basis","Adjusted EBITDA $1.2B, up ~2% on same basis; new product revenues $210M in the quarter","Raises 2024 new product revenue guidance to $500M-$600M; expects FY total revenue growth ~2% on divestiture-adjusted operational basis"],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":7460000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211005,"accession_number":"0001193125-24-174684","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Viatris closes €1.95B divestiture of over-the-counter business to Cooper Consumer Health","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received €1.85B cash at closing (subject to adjustments) and up to €100M contingent additional consideration.","Buyer paid €25M advance toward transition services fees at closing.","€120M of closing consideration retained by buyer for pending sale of select geography portions.","Transaction closed on July 3, 2024, as previously announced in January 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229492,"accession_number":"0001193125-24-152351","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris appoints Dr. Rogério Vivaldi Coelho to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective June 3, 2024; expands Board from 11 to 12 members.","Dr. Vivaldi joins the reestablished Science and Technology Committee.","Former CEO of Sigilon Therapeutics (acquired by Eli Lilly, 2023) and executive at Bioverativ, Spark Therapeutics, and Genzyme.","Led successful approval of more than 15 orphan products across 20+ countries during Genzyme tenure.","Will receive standard compensation for non-employee directors; indemnification agreement executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229491,"accession_number":"0001792044-24-000014","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris reports strong Q1: revenue $3.66B, adj. EPS $0.67, free cash flow $565M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $3.66B, GAAP net earnings $113.9M; adjusted EBITDA $1.19B; GAAP EPS $0.09, adjusted EPS $0.67.","Fourth consecutive quarter of operational revenue growth on a divestiture-adjusted basis; total sales declined 2% GAAP but grew 2% adjusted.","Closed Idorsia collaboration and Women's Healthcare divestiture; expects API divestiture imminent.","Returned $393M to shareholders in Q1 via dividends and share repurchases; declared quarterly dividend of $0.12 per share.","Reaffirmed 2024 guidance: new product revenue $450-550M; free cash flow target reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":3663400000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248035,"accession_number":"0001792044-24-000004","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris FY23 rev $15.4B, adj EBITDA $5.1B; 2024 guidance; $1B buyback boost; Idorsia deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY23 total revenues $15.4B, U.S. GAAP net earnings $54.7M, adjusted EBITDA $5.1B, free cash flow $2.4B.","Reports third consecutive quarter of operational revenue growth on divestiture-adjusted basis; expects continued growth in 2024.","Enters global R&D collaboration with Idorsia for two Phase 3 assets selatogrel and cenerimod with blockbuster potential.","Board increases share repurchase authorization by $1B to $2B; maintains $0.48 annual dividend, declares $0.12 Q1 dividend.","Completed $250M in share repurchases in 2024 to date; guidance for 2024 provided."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":15426900000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248034,"accession_number":"0001193125-24-019472","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K/A","filed_at":"2024-01-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Viatris signs definitive agreement to sell OTC business to Cooper Consumer Health","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Viatris exercised put option on Jan 26, 2024; signed Transaction Agreement on Jan 29, 2024.","Sale includes substantially all OTC products business; consideration includes estimated cash and contingent additional amount (undisclosed).","Closing conditions include European Commission, French Ministry approvals; Italian and Serbian consents already obtained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265501,"accession_number":"0001193125-23-296756","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris appoints Doretta Mistras as CFO effective March 1, 2024; Philippe Martin as Chief R&D Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sanjeev Narula to step down as CFO on March 1, 2024; will receive severance of 2x base salary and target bonus.","Theodora 'Doretta' Mistras, former Citigroup MD, appointed CFO effective March 1, 2024; base salary $825k, target bonus 100%, LTI 400%.","Mistras receives $500k cash sign-on and $500k RSUs subject to vesting/repayment conditions.","Philippe Martin appointed Chief R&D Officer; previously led development of Otezla and Zeposia at Celgene.","Changes are part of Viatris's preparation for Phase 2 of its strategic plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265500,"accession_number":"0001193125-23-296654","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Viatris amends bylaws and shareholders approve all proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended bylaws effective Dec 15, 2023, updating universal proxy rules and Delaware law procedures.","All 11 director nominees elected; say-on-pay proposal approved with 84.7% of votes cast in favor.","Ratification of Deloitte & Touche as auditor for FY2023 approved; >94% for.","Charter amendments adding federal forum selection and officer exculpation passed.","Broker non-votes were present on most proposals but did not affect outcomes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265499,"accession_number":"0001193125-23-296644","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viatris Chairman Coury transitions to Chairman Emeritus; Higgins elected new Board Chair","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Robert J. Coury steps down as Executive Chairman, becomes Chairman Emeritus and Strategic Advisor; Melina Higgins elected as Board Chair.","Viatris achieved $1B in synergies as planned, returned ~$1.8B to shareholders, and paid down ~$6.6B in debt, targeting 3x leverage.","Phase 2 (2024+) focuses on growth: investing in pipeline, strategic licensing/partnerships, and opportunistic M&A; returning ~50% FCF to shareholders.","Scott A. Smith continues as CEO with new organizational structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265493,"accession_number":"0001193125-23-296763","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K/A","filed_at":"2023-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Viatris assigns director Leo Groothuis to three committees; consolidates compliance & risk oversight committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leo Groothuis appointed to Compliance and Risk Oversight, Executive, and Governance and Sustainability Committees.","Board consolidated the Compliance Committee and Risk Oversight Committee into the Compliance and Risk Oversight Committee.","Board renamed Governance and Nominating Committee to Governance and Sustainability Committee.","All changes effective immediately after the 2023 annual meeting of shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265498,"accession_number":"0001792044-23-000031","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q3 2023: Revenue $3.94B, net earnings $332M, reaffirms FY adj. EBITDA and FCF guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3.94B; U.S. GAAP net earnings $332M; adjusted EBITDA $1.36B; free cash flow $738M.","Second consecutive quarter of YoY operational revenue growth on a divestiture-adjusted basis.","Reaffirms full-year 2023 adjusted EBITDA and free cash flow guidance; revises revenue guidance for FX.","Declares quarterly dividend of $0.12 per share.","On track to complete all planned divestitures by the end of H1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":11589600000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265497,"accession_number":"0001193125-23-261705","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-10-24T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Viatris reduces board to 11 directors; director Pauline van der Meer Mohr to retire Dec 15, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size reduced to 11 directors effective after the 2023 annual meeting on December 15, 2023.","Director Pauline van der Meer Mohr to retire from the Board effective December 15, 2023 and is not nominated for re-election.","Change follows regular Board evaluation process; no replacement announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265496,"accession_number":"0001193125-23-260013","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-10-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris President Rajiv Malik to Retire; President Anthony Mauro to Depart in Restructuring","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rajiv Malik, President, will retire as executive effective April 1, 2024, and remain on the Board and consult.","Anthony Mauro, President Developed Markets, will depart April 1, 2024, due to position elimination in commercial realignment.","Malik's outstanding equity awards continue vesting during service; Mauro receives severance of 2x salary and bonus.","Mauro's unvested equity awards forfeited unless otherwise provided; both departures support CEO transition and restructuring.","Press release issued October 20, 2023, detailing Malik's retirement and continued board service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265495,"accession_number":"0001193125-23-249206","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Viatris enters agreement to sell OTC business to Cooper Consumer Health for up to €1.95B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Up to €1.95B cash consideration: €1.85B at closing plus up to €100M contingent on return multiple.","Option exercisable by Viatris after employee consultations; expires Feb 2, 2024.","Closing subject to regulatory approvals from EU Commission, Serbia, France, and Italy.","Viatris to provide transition services; €25M advance payment at closing for TSA fees.","€120M of consideration retained by buyer for future sale of select geographies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265494,"accession_number":"0001193125-23-248059","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viatris announces $6.94B in gross proceeds from remaining divestitures, achieving >12x multiple","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Aggregated gross proceeds up to $6.94B from biosimilars, OTC, API, Women's Health, and non-core markets.","OTC offer: gross consideration up to ~$2.17B (12.8x multiple); API/Women's Healthcare: up to ~$1.2B (9.9x).","Strategic decision to retain Viagra, Dymista, select OTC in certain markets; retained value ~$1.6B.","Divestitures expected to close by end of H1 2024; net proceeds to be used for debt paydown targeting 3.0x gross leverage.","Up to 12 facilities and >6,000 employees (15% workforce) may be conveyed, simplifying organization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282708,"accession_number":"0001792044-23-000021","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris reports strong Q2 2023: revenue $3.92B, net income $264M, reaffirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3.92B, U.S. GAAP net earnings $264M, adjusted EBITDA $1.31B, free cash flow $447M.","Reaffirms full-year 2023 total revenues, adjusted EBITDA and free cash flow expected at midpoint of guidance ranges.","Board declared $0.12/share dividend, payable Sept 15, record Aug 24 (unchanged from prior).","Paid down $727M debt YTD; on track to announce planned divestitures in 2023, with at least one significant in Q3.","Launched Breyna (generic Symbicort) in July; new product revenue target on track."],"consensus_eps_estimate":null,"consensus_eps_actual":0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":7647700000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301991,"accession_number":"0001193125-23-149905","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-05-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris Exec Chairman Coury to step down; stays as Emeritus through 2025 with $15M/yr fee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Coury transitions to Chairman Emeritus & Senior Strategic Advisor after 2023 annual meeting (mid-Dec).","Coury will not stand for re-election; ceases as director/officer/employee at meeting conclusion.","Coury receives $15 million annual consulting fee for 2024-2025, paid monthly.","Board will select new independent chair; announcement expected in coming months.","Leo Groothuis appointed independent director, filling vacancy from Michael Goettler's departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301990,"accession_number":"0001792044-23-000014","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q1 revenue $3.73B, net earnings $225M, adjusted EBITDA $1.34B; reaffirms full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $3.73B; US GAAP net earnings $225M; adjusted EBITDA $1.34B; free cash flow $923M.","Debt paydown of $546M in Q1; total ~$6B since 2021.","Returned ~$400M to shareholders: $250M share repurchases (21.2M shares) and dividends.","Board declared $0.12 quarterly dividend payable June 16, 2023 to holders of record May 24.","Reaffirmed 2023 revenue, adjusted EBITDA and FCF guidance at midpoint; 2024 Phase 2 outlook unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":3729100000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321706,"accession_number":"0001792044-23-000005","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris reports FY2022 revenue $16.3B, meets adjusted guidance; provides 2023 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2022 total revenues $16,263M; adjusted EBITDA $5,777M; free cash flow $2,547M.","2023 guidance midpoint implies revenue growth over 2022 excluding full-year biosimilars impact; reaffirms 2024 Phase 2 outlook.","Board approves 2023 dividend policy of $0.48 per share annually; Q1 dividend $0.12 per share declared.","Completed $250M in share repurchases; paid down ~$3.3B debt in 2022, $5.4B since 2021.","On track to execute planned divestitures; biosimilars transaction closed in Q4 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":16262700000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321705,"accession_number":"0001193125-23-050797","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris appoints Scott A. Smith as CEO effective April 1, 2023; Michael Goettler departs","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott A. Smith, former Celgene President/COO, appointed CEO effective April 1, 2023 to lead Phase 2 strategy.","Michael Goettler to support transition and depart; separation not due to any disagreement with company.","Smith's compensation: $1.4M base salary, 150% target bonus, 700% LTI (800% for 2023).","Severance: 1x base+bonus if terminated before June 30, 2024; 2x after; 2.5x on change in control.","Smith has been a Viatris board member since December 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321704,"accession_number":"0001193125-23-050806","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K/A","filed_at":"2023-02-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Viatris appoints Elisha Finney to Audit and Finance Committees; Scott Smith not assigned to any committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Elisha Finney appointed to Audit Committee and Finance Committee effective February 24, 2023.","Scott Smith not appointed to any Board committee.","Amendment to December 29, 2022 8-K reporting initial board appointments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339801,"accession_number":"0001193125-22-314765","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2022-12-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Viatris appoints Elisha Finney and Scott Smith to Board; Dimick and Read retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Neil Dimick and Ian Read retired from Viatris board effective Dec 28, 2022; no disagreement with company.","Elisha Finney (former Varian CFO) and Scott Smith (BioAtla President, ex-Celgene) appointed as Class I directors effective Dec 29, 2022.","Finney serves on boards of Mettler-Toledo, NanoString, ICU Medical; Smith is Chairman of Triumvira, board member of Apexigen and Refuge.","Robert Coury, Executive Chairman, thanked retiring directors and welcomed new appointees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339800,"accession_number":"0001193125-22-301842","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Viatris 2022 annual meeting elects directors, approves exec compensation, rejects independent chair proposal","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All four Class II directors elected with 739M-831M votes in favor; no broker non-votes counted.","Say-on-pay for 2021 compensation approved: 763.1M for, 78.4M against (90.7% support).","Ratification of Deloitte & Touche as FY2022 auditor approved: 943.0M for, 54.0M against.","Shareholder proposal for independent board chairman rejected: 386.3M for vs 454.6M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339799,"accession_number":"0000950157-22-001253","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Viatris closes $3.335B biosimilars sale to Biocon Biologics; receives $2B cash and 12.9% equity stake","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration: $2B cash at close, $1B convertible preferred equity (12.9% stake), plus $335M in future cash payments in 2024.","2022 revenue expected ~$80M lower and adjusted EBITDA ~$20M lower due to transaction; ~$400M in deal-related expenses incurred.","Net proceeds to be used to pay down short-term debt, fund ~$700-750M ophthalmology acquisitions (Q1 2023), and initiate share buybacks in 2023.","Viatris and Biocon Biologics entered a 2-year Transition Services Agreement for business continuity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339798,"accession_number":"0001792044-22-000034","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q3 revenue $4.08B, adj EBITDA $1.50B; reaffirms FY guidance; debt paydown ahead of schedule","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $4.08B; U.S. GAAP net earnings $354M; Adjusted EBITDA $1.50B.","Year-to-date operating cash flow $2.81B; free cash flow $2.56B; debt reduction $2.1B ahead of schedule.","Board declares $0.12 quarterly dividend; reaffirms 2022 guidance for revenues, adjusted EBITDA, FCF.","Q3 free cash flow $765M; operating cash flow $869M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":12386700000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339797,"accession_number":"0001193125-22-278606","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Viatris acquires Oyster Point Pharma and Famy Life Sciences for $700-750M to create ophthalmology franchise","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Aggregate purchase price $700-750M cash; Oyster Point at $11/share upfront plus up to $2 CVR; expects Q1 2023 close.","Sees combined ops adding at least $1B net sales and $500M adj. EBITDA by 2028; expects acquisitions to be adjusted EPS accretive in 2023.","Reaffirms total pre-tax proceeds from Biocon Biologics and non-core asset divestitures up to ~$9B; plans $1B stock repurchase program in 2023.","Provides 2024-2028 financial targets: total revenue CAGR ~3%, adj. EBITDA CAGR ~4-5%, adj. EPS CAGR ~mid-teens.","Ophthalmology division to be led by current Oyster Point CEO Jeff Nau upon closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357124,"accession_number":"0001792044-22-000026","cik":1792044,"company_name":"Viatris Inc","ticker":"VTRS","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Viatris Q2 2022: Revenue $4.12B, adj. EBITDA $1.48B, reaffirms guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $4.12B; U.S. GAAP net earnings $314M; adjusted EBITDA $1.48B.","Free cash flow $719M in Q2; H1 free cash flow ~$1.8B.","Reaffirms adjusted EBITDA and free cash flow guidance; revises total revenue guidance for FX.","Declares quarterly dividend $0.12 per share; paid down ~$1.5B debt in H1, on track for $2B full year.","Biocon Biologics transaction on track for H2 2022 close."],"consensus_eps_estimate":null,"consensus_eps_actual":0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":8308500000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18830820000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-08T23:59:59+00:00|357124"}